文献速递心脑血管急症

收缩压、阿司匹林与氯吡格雷使用及卒中复发:POINT试验分析

Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial.
PubMed 文献 · JAMA Netw Open · 2021-06-01
一句话结论POINT试验事后分析:基线收缩压<140 mmHg的轻型缺血性卒中/TIA患者,90天双联抗血小板治疗较阿司匹林单药显著降低缺血性卒中复发(HR 0.36)。

该研究为POINT试验的事后队列亚组分析,纳入4781例急性轻型缺血性卒中或TIA患者,按基线收缩压<140 mmHg vs ≥140 mmHg分层,比较双联抗血小板治疗(DAPT)与阿司匹林单药对90天内缺血性卒中复发的影响。结果显示收缩压与治疗的交互项显著(P=0.03);收缩压<140 mmHg亚组DAPT较阿司匹林单药显著降低缺血性卒中风险(HR 0.36,95%CI 0.18-0.72,P=0.004),而≥140 mmHg亚组无统计学显著差异(HR 0.79,95%CI 0.60-1.02,P=0.08)。7天内缺血性卒中交互项亦显著(P=0.02),收缩压<140 mmHg亚组HR 0.19(95%CI 0.07-0.55,P=0.002)。作者认为基线收缩压较低者从90天DAPT中获益更大,尤其对早期卒中复发的减少。

要点

  • 在基线收缩压<140 mmHg的轻型缺血性卒中/TIA患者中,DAPT较阿司匹林单药显著降低90天内缺血性卒中风险(HR 0.36,95%CI 0.18-0.72,P=0.004)。
  • 基线收缩压≥140 mmHg亚组中,DAPT与阿司匹林单药相比未达统计学显著差异(HR 0.79,95%CI 0.60-1.02,P=0.08)。
  • 收缩压与治疗交互项对90天缺血性卒中显著(P=0.03),对7天内缺血性卒中亦显著(P=0.02)。
  • 7天内缺血性卒中:收缩压<140 mmHg亚组DAPT的HR为0.19(95%CI 0.07-0.55,P=0.002)。
  • 作者认为需进一步研究重复这些发现,并可能检验卒中发作12小时内轻度降低收缩压联合DAPT是否降低早期卒中复发风险。

适用人群与场景

  • POINT试验纳入的急性轻型缺血性卒中或TIA患者,且有可用血压和结局数据者;共4781例,平均(SD)年龄64.6(13.1)岁,男性2142例(44.8%),白人3487例(72.9%)。

诊断标准与关键阈值

  • 基线收缩压分层:<140 mmHg(946例,19.8%) vs ≥140 mmHg(3835例,80.2%)。

处置流程与药物剂量

  • DAPT(阿司匹林联合氯吡格雷)与阿司匹林单药比较,疗程90天;原文未给出具体剂量方案。

研究设计与关键结果

  • 研究类型:POINT试验的事后队列亚组分析;POINT为多中心试验,2010至2018年在北美、欧洲、澳大利亚和新西兰的10个国家269个中心开展。
  • 主要终点:90天随访期间缺血性卒中,共266例(5.6%)发生主要终点。
  • 收缩压与治疗交互项对90天缺血性卒中显著(P for interaction=0.03)。
  • 收缩压<140 mmHg亚组:DAPT vs 阿司匹林单药缺血性卒中HR 0.36(95%CI 0.18-0.72;P=0.004)。
  • 收缩压≥140 mmHg亚组:DAPT vs 阿司匹林单药缺血性卒中HR 0.79(95%CI 0.60-1.02;P=0.08)。
  • 7天内缺血性卒中:交互项显著(P for interaction=0.02),收缩压<140 mmHg亚组DAPT的HR 0.19(95%CI 0.07-0.55;P=0.002)。
  • Cox比例风险模型校正了患者年龄、种族、病前高血压、糖尿病和合格事件的最终诊断(卒中 vs TIA)。

证据类型、等级与局限

  • 证据类型:基于多中心随机对照试验的事后队列亚组分析。
  • 局限:原文未报告局限性;作者在结论中提出需进一步研究重复这些发现,并可能检验卒中发作12小时内轻度降低收缩压联合DAPT是否降低早期卒中复发风险。

对床旁实践的改变

  • 在POINT试验中,就诊时收缩压<140 mmHg的患者接受90天DAPT较基线收缩压较高者获益更大,尤其对减少早期缺血性卒中复发;作者认为需进一步研究重复这些发现,并可能检验卒中发作12小时内轻度降低收缩压联合DAPT是否降低早期卒中复发风险。

指南或共识出处

  • POINT试验(Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke),JAMA Network Open发表。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Elevated systolic blood pressure (SBP) after acute ischemic stroke and transient ischemic attack (TIA) is associated with future stroke risk.

OBJECTIVE: To explore the association of dual antiplatelet therapy (DAPT) with stroke recurrence among patients with acute ischemic stroke and TIA with or without elevated baseline SBP.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study performed a post hoc subgroup analysis of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, which was a multicenter trial conducted from 2010 to 2018 at 269 sites in 10 countries in North America, Europe, Australia, and New Zealand. Patients enrolled in POINT with available blood pressure and outcome data were included in this cohort. Statistical analysis was performed from November 2020 to January 2021.

EXPOSURES: Baseline SBP less than 140 mm Hg vs greater than or equal to 140 mm Hg and the interaction term of SBP (<140 mm Hg vs ≥140 mm Hg) × treatment group (aspirin vs DAPT).

MAIN OUTCOMES AND MEASURES: The primary outcome was ischemic stroke during 90 days of follow-up. The statistical analysis fit Cox proportional hazards models adjusted for patient age, race, premorbid hypertension, diabetes, and final diagnosis of the qualifying event (stroke vs TIA).

RESULTS: Among 4781 patients in the cohort, the mean (SD) age was 64.6 (13.1) years; 2142 (44.8%) were male individuals, 3487 (72.9%) were White individuals, and 266 (5.6%) had a primary outcome of ischemic stroke during follow-up. There were 946 patients (19.8%) with baseline SBP less than 140 mm Hg and 3835 (80.2%) with SBP greater than or equal to 140 mm Hg. The interaction term (SBP × treatment) was significant (P for interaction = .03). In the subgroup of patients with SBP less than 140 mm Hg, the hazard ratio (HR) of DAPT vs aspirin alone for ischemic stroke was 0.36 (95% CI, 0.18-0.72; P = .004), whereas the HR in the subgroup with SBP greater than or equal to 140 mm Hg was 0.79 (95% CI, 0.60-1.02; P = .08). When evaluating the outcome of ischemic stroke within 7 days of randomization, the interaction term was significant (P for interaction = .02), and the HR for patients with DAPT with SBP less than 140 mm Hg was 0.19 (95% CI, 0.07-0.55; P = .002).

CONCLUSIONS AND RELEVANCE: In the POINT trial, patients with SBP less than 140 mm Hg at presentation received a greater benefit from 90 days of DAPT than those with higher baseline SBP, particularly for reduction of early ischemic stroke recurrence. Additional research is needed to replicate these findings and potentially test whether mild SBP reduction and DAPT within 12 hours of stroke onset lowers early risk of stroke recurrence.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. de Havenon A, Johnston SC, Easton JD, et al. Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. JAMA Netw Open. 2021. PMID: 34086033. doi:10.1001/jamanetworkopen.2021.12551

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。